Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
|Videos|March 27, 2019
Relapsed/Refractory Multiple Myeloma
Relapsed/Refractory Multiple Myeloma
Advertisement
Case: 75-Year-Old Man With Symptomatic R/R Multiple Myeloma
January 2015
- A 75-year-old man was diagnosed with multiple myeloma; R-ISS stage I
- PMH: hypertension; coronary artery disease post stent placement
- Patient was treated with lenalidomide + dexamethasone for 9 months; transplant-ineligible due to age and performance status
- Patient achieved a VGPR, discontinued treatment thereafter due to patient request
September 2018
- On routine follow-up 3 years later, patient presents with new-onset back pain and generalized fatigue
- Imaging: multiple new lytic lesions with compression fractures
- Laboratory results:
- Hb, 10.7 g/dL
- Ca2+, 9.3 mg/dL
- Creatinine, 1.1 mg/dL
- M-protein, 3.2 g/dL
- Cytogenetics/FISH: del (17p) discovered at relapse
- ECOG PS: 2
Advertisement
Related to this article
In the phase 3 EXCALIBER-RRMM trial, iberdomide plus daratumumab and dexamethasone doubled MRD-negative complete response rates over standard therapy in relapsed myeloma.
Closing sessions at IMS 2026 featured MRD-guided treatment strategies, real-world CAR T-cell data, and mixed results on cilta-cel neurotoxicity prevention in myeloma.
Etentamig significantly improved response and survival over standard therapy in the phase 3 CERVINO trial, headlining day 3 of IMS 2026 myeloma coverage.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
Half of patients who stopped MRD-guided maintenance in GEM2014MAIN remained progression-free at 7 years, as IMS 2026 also featured DREAMM-9, MIDAS, and novel bispecific data.
A new IMS/IMWG consensus definition requires 5 years of treatment-free, MRD-negative remission before multiple myeloma can be called cured.
Mezigdomide plus elranatamab yielded a 100% ORR in MELT-MM, as other IMS 2026 abstracts covered cevostamab, anito-cel vs cilta-cel, and linvoseltamab in HR-SMM.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Anito-Cel Delivers Durable Responses With Low Neurotoxicity in RRMM
2
Risk, Histology, and Metastatic Site Guide First-Line RCC Treatment Choices
3
FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer
4
Frontline CAR T and Bispecific Antibodies Are the Next Frontier in Myeloma
5